Teva FCA Trial Delayed by Review of Kickback Causation Standard
Law360 – A district court judge has delayed an FCA trial that could cost Teva Pharmaceuticals $10 billion, to allow the First Circuit to address questions regarding the causation standard under the Anti-Kickback Statute.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.